All In Biotech

BLA 761119 · Lundbeck Seattle Biopharmaceuticals, Inc.

Vyepti

Eptinezumab-Jjmr · Injection · Calcitonin Gene-related Peptide Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Feb 21, 2020

Approved uses

3

Original approval plus efficacy supplements

Registered trials

30

16 Phase 3, 9 recruiting

FAERS reports

9,754

2,514 serious, 68 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 5, 2026.

VYEPTI is indicated for the preventive treatment of migraine in adults. VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults ( 1 )

Mechanism: Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 22, 2025 Supplement 11 · Efficacy LetterLabel
  • Aug 18, 2025 Supplement 10 · Efficacy
  • Feb 21, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • VYEPTI · EPTINEZUMAB-JJMR 100MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Eptinezumab" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,135
  • migraine1,565
  • headache1,024
  • therapeutic response shortened602
  • nausea575
  • fatigue526
  • throat irritation384
  • drug effect less than expected383
  • dizziness382
  • pruritus343
  • nasal congestion275
  • dyspnoea229

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
20192
2020156
2021750
20221,262
20231,668
20242,246
20252,064
20261,604

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vyepti (Eptinezumab-Jjmr)

2024 spending

$15.1M

Beneficiaries

1,502

3,789 claims

Per beneficiary

$10,020

$1,657.25 per unit

View as table
YearSpending
2020$480,832
2021$2,345,427
2022$4,668,437
2023$8,873,945
2024$15,050,143

Part B: Vyepti (Eptinezumab-Jjmr) · HCPCS J3032

2024 spending

$70.6M

Beneficiaries

6,392

17,819 claims

Per beneficiary

$11,049

2024 ASP limit $18.36 per unit

View as table
YearSpending
2020$1,155,143
2021$12,936,886
2022$25,996,801
2023$45,074,964
2024$70,625,022

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 97 on PubMed

Sponsor: Lundbeck Seattle Biopharmaceuticals, Inc.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.